Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults

Plain-language summary

Published 2018 in Nature Communications, this work by Martens CR and collaborators tackles a specific question within nr-focused NMN/NAD+ research.

Key findings reported by the authors

• 500mg twice daily NR safely raised NAD+
• Trend toward reduced systolic BP in stage-1 hypertensives
• Healthy 55-79yo adults

What this means for Malaysian buyers

For readers in Malaysia weighing whether to start or continue NMN supplementation, this paper sits at the strong end of the evidence spectrum. Strong-tier human placebo-controlled trial data carries the most weight in our editorial framework - treat findings as actionable signal, but always pair with at least one replication. Findings here are most directly relevant to nr decisions, with secondary relevance to cardiovascular and clinical-trial. Our editorial methodology weights human placebo-controlled trials above mouse mechanistic work above review articles.